ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Feasibilty of Hepatitis C NAT Positive Kidney Transplant into Hepatitis C Negative Recipients as Standard of Care

T. Kaur, J. Choi, N. Anwar, M. Anand, S. Shah, S. Bumb, B. Abu Jawdeh, S. Shah, T. Diwan, A. Govil

University of Cincinnati Medical Center, Cincinnati, OH

Meeting: 2020 American Transplant Congress

Abstract number: 340

Keywords: Cadaveric organs, Hepatitis C, Kidney transplantation, Outcome

Session Information

Session Name: Kidney Deceased Donor Selection II

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:27pm-4:39pm

Location: Virtual

*Purpose: With advent of direct acting antivirals (DAA) for Hepatitis (Hep) C which have a 96-100% sustained viral remission(SVR), doors have opened for using Hep C nucleic acid amplification testing (NAT)+ kidneys and treat the patients for acquired Hep C post-transplant. We performed a prospective IRB approved trial at our center to validate the use and challenges of this approach.

*Methods: Hep C NAT negative patients on the kidney transplant wait list were approached and informed consent was obtained. Treatment was planned post transplant after approval was obtained from their insurance company. In addition, our center agreed to cover the treatment cost if denied by insurance company. Patients with Hep C related kidney disease, chronic liver disease, dual organ transplants, HIV and Hep B infection were excluded. Post-transplant, they were tested for Hep C viral load and genotype starting day 3, 7 and weekly thereafter until Hep C viremia was confirmed. DAA was prescribed by hepatologist according to the Hep C genotype and insurance company preference. Standard of care immunosuppression protocols and post-transplant monitoring was done.

*Results: 35 patients received Hep C NAT+ kidneys between 10/2018- 10/2019 (80% males, 20% females). Median age of the recipients was 53 years (range 29-72). Blood group distribution was 18(51%), 14(40%), 2(6%) and 1(3%) patients for O, A, B and AB blood group respectively. Mean waiting time for recipients was 820 ± 654 days. Mean KDPI was 56 ±15 with a median donor age of 38 years (range 22-56). All patients became viremic between day 7-10. 57 % (20) had genotype 1a, 28% (10) had 3 and 14 %( 5) had 2b. 5 pts had transient transaminitis (>2X AST/ALT). All patients got their Hep C treatment approved through their insurance. Median time from transplant to DAA initiation day was 43 days (range 15-94). As of Nov. 2019, 33/35 (94%) patients have been treated and all (100%) have become Hep C RNA negative (end of treatment response EOT) with 16 patients (48%) achieving 12-week SVR. The remaining 2 patients are yet to start the therapy. The kidney function has remained stable during and after the course of treatment (fig.1). 1 patient had glomerulonephritis recurrence and 1 patient had tubuloreticular inclusions on allograft biopsy attributed to Hep C infection.

*Conclusions: Transplantation of Hep C NAT positive kidneys to Hep C negative recipient followed by treatment of Hep C is a feasible option as a standard of care outside the sponsored trials. Recipient should be closely monitored for Hep C related kidney complications.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kaur T, Choi J, Anwar N, Anand M, Shah S, Bumb S, Jawdeh BAbu, Shah S, Diwan T, Govil A. Feasibilty of Hepatitis C NAT Positive Kidney Transplant into Hepatitis C Negative Recipients as Standard of Care [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/feasibilty-of-hepatitis-c-nat-positive-kidney-transplant-into-hepatitis-c-negative-recipients-as-standard-of-care/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences